Since prior results have shown a link between loss of MED12 and hyperactivation of GLI3-mediated SHH signaling in prostate cancer and X-linked intellectual disability syndromes, we performed quantitative PCR to determine whether dysregulated signaling also occurs in breast cancer cells. This evidence concerns the gene MED12 and breast carcinoma.